Tesla
TSLA
MicroStrategy
MSTR
MARA Holdings
MARA
Apple
AAPL
Microsoft
MSFT
US Stock MarketDetailed Quotes
BCRX BioCryst Pharmaceuticals
- 7.530
- -0.070-0.92%
Close Dec 13 16:00 ET
- 7.500
- -0.030-0.40%
Post 20:01 ET
1.56BMarket Cap-12.34P/E (TTM)
7.630High7.435Low1.60MVolume7.560Open7.600Pre Close12.02MTurnover0.83%Turnover RatioLossP/E (Static)207.13MShares8.88052wk High-3.33P/B1.46BFloat Cap4.03052wk Low--Dividend TTM193.36MShs Float37.250Historical High--Div YieldTTM2.57%Amplitude0.600Historical Low7.522Avg Price1Lot Size
Trending US Stocks
Fed Rate Cut Beneficiaries Fed Rate Cut Beneficiaries
Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data. Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data.
BioCryst Pharmaceuticals Stock Forum
BioCryst Pharmaceuticals | SC 13G/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-The Vanguard Group(9.81%)
Larger Image: tradingview.com...
$BioCryst Pharmaceuticals (BCRX.US)$
Benzinga· 3 mins ago
BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced new real-world evidence on the use of oral, once-daily ORLADEYO (berotralstat) demonstrating that patients with hereditary angioedema (HAE) in the United States experience significant reductions in healthcare resource utilization (HRU), including significant reduc...
Just
U.S. Government Awards BioCryst $69 Million Rapivab® (Peramivir Injection) Contract for Strategic National Stockpile
Jefferies analysts cited 10 possible policies that Tr...
—Q1 2024 ORLADEYO net revenue grows 30 percent y-o-y to $88.9 million—
—Full-year 2024 ORLADEYO revenue guidance adjusted to $390-$400 million (top end of prior guidance range) —
—Pipeline programs, including BCX17725 for Netherton syndrome and avoralstat for DME, advancing on schedule into clinical trials—
No comment yet